April 22, 2024
OncoSpherix to Showcase Breakthrough Oncology Innovations at Premier Biotech Event
Atlanta, GA – Apr 2025 – OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, is excited to announce its participation in Portal Innovations’ ‘Rising Stars in Oncology’ event during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago.
The event, taking place on April 25, 2025, will spotlight emerging biotech companies developing breakthrough cancer treatments. OncoSpherix will present its latest advancements in targeting the hypoxia-inducible factor 1 (HIF-1) pathway, thereby disrupting essential processes that fuel tumor growth, metastasis, and resistance to therapy.
“We are honored to be recognized as a rising innovator in oncology,” said OncoSpherix CEO, Margaret Offermann, MD, PhD. “This event provides a unique platform to share our mission and engage with leading investors, researchers, and industry experts.”
The ‘Rising Stars in Oncology’ event, hosted by Portal Innovations, brings together cutting-edge biotech companies, venture investors, and scientific leaders to showcase promising advancements in cancer therapeutics.
For more details on the event, visit: https://hs.portalinnovations.com/2025-aacr.
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications, in combination with agents that show therapeutic synergy while being well-tolerated as part of the combination.
Company Contact:
Allan Valmonte
VP of Business Operations
Source: OncoSpherix, Inc.